AlgoNomics NV
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AlgoNomics NV - overview
Established
1999
Location
Gent, -, Belgium
Primary Industry
Biotechnology
About
AlgoNomics NV provides integrated immunogenicity services for the development of biopharmaceuticals.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Company Stage
Acquired
Total Amount Raised
Subscriber access only
AlgoNomics NV - financials
| Fiscal Year Ended | Dec 31, 2002 | Dec 31, 2003 | Dec 31, 2004 | Dec 31, 2005 | Dec 31, 2006 | Dec 31, 2007 | Dec 31, 2008 | Dec 31, 2009 | Dec 31, 2010 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 173,000 | 50,000 | 526,000 | 662,000 | 752,000 | 977,000 | 2,172,654 | - | - | - |
| % Revenue Growth (YoY) | - | (71.1%) | 952.0% | 25.9% | 13.6% | 29.9% | 122.4% | - | - | - |
| EBITDA (USD) | (625,000) | (762,000) | (26,000) | 81,000 | (115,000) | (471,000) | 67,233 | - | - | - |
| Operating Income (USD) | (743,000) | (867,000) | (104,000) | 29,000 | (165,000) | (543,000) | (25,081) | - | - | - |
| Operating Margin | (429.5%) | (1734.0%) | (19.8%) | 4.4% | (21.9%) | (55.6%) | (1.2%) | - | - | - |
| % EBITDA Margin | (361.3%) | (1524.0%) | (4.9%) | 12.2% | (15.3%) | (48.2%) | 3.1% | - | - | - |
| NET Income (USD) | (703,000) | (858,000) | (132,000) | 1,000 | (197,000) | (539,000) | 486,898 | - | - | - |
| % Net Margin | (406.4%) | (1716.0%) | (25.1%) | 0.2% | (26.2%) | (55.2%) | 22.4% | - | - | - |
AlgoNomics NV - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.